JP2010501188A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501188A5
JP2010501188A5 JP2009525796A JP2009525796A JP2010501188A5 JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5 JP 2009525796 A JP2009525796 A JP 2009525796A JP 2009525796 A JP2009525796 A JP 2009525796A JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5
Authority
JP
Japan
Prior art keywords
composition
rna molecule
interfering rna
nucleotides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/076776 external-priority patent/WO2008024983A2/en
Publication of JP2010501188A publication Critical patent/JP2010501188A/ja
Publication of JP2010501188A5 publication Critical patent/JP2010501188A5/ja
Pending legal-status Critical Current

Links

JP2009525796A 2006-08-24 2007-08-24 IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 Pending JP2010501188A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83982606P 2006-08-24 2006-08-24
PCT/US2007/076776 WO2008024983A2 (en) 2006-08-24 2007-08-24 Rnai-mediated inhibition of gremlin for treatment of iop-related conditions

Publications (2)

Publication Number Publication Date
JP2010501188A JP2010501188A (ja) 2010-01-21
JP2010501188A5 true JP2010501188A5 (enExample) 2010-08-12

Family

ID=39032079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525796A Pending JP2010501188A (ja) 2006-08-24 2007-08-24 IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害

Country Status (11)

Country Link
US (3) US20080051361A1 (enExample)
EP (1) EP2059597A2 (enExample)
JP (1) JP2010501188A (enExample)
KR (1) KR20090042297A (enExample)
CN (2) CN101517081A (enExample)
AU (1) AU2007286545A1 (enExample)
BR (1) BRPI0715821A2 (enExample)
CA (1) CA2659464A1 (enExample)
MX (1) MX2009001896A (enExample)
WO (1) WO2008024983A2 (enExample)
ZA (1) ZA200900553B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
AU2008308784B2 (en) * 2007-10-01 2013-07-18 Arrowhead Research Corporation Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders
BRPI0802525A2 (pt) 2008-07-11 2010-03-09 Kiyoshi Hashiba endoscópio cirúrgico
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2011072091A1 (en) * 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
PL2796150T3 (pl) 2011-12-15 2021-08-30 Bioneer Corporation Nowe koniugaty oligonukleotydowe i ich zastosowanie
KR101722948B1 (ko) 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법
RU2577227C1 (ru) 2012-01-05 2016-03-10 Байонир Корпорейшн Высокоэффективная двухспиральная олиго-рнк конструкция типа наночастицы и способ ее изготовления
JP5906327B2 (ja) 2012-01-18 2016-04-20 バイオニア コーポレーションBioneer Corporation 磁性ナノ粒子−SAMiRNA複合体およびその製造方法
WO2013137686A1 (ko) * 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
AU2012389270B2 (en) * 2012-09-05 2018-11-08 Sylentis S.A.U. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2917299C (en) 2013-07-05 2020-07-21 Bioneer Corporation Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
WO2015132303A1 (en) 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1966725A (zh) * 2001-10-31 2007-05-23 爱尔康公司 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets

Similar Documents

Publication Publication Date Title
RU2008130857A (ru) Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза
RU2008150324A (ru) Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний
RU2011124528A (ru) ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ
JP2008525460A5 (enExample)
Guzman‐Aranguez et al. Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy
RU2007132874A (ru) Phki-опосредованное ингибирование мишеней повышенного внутриглазного давления
CN110846316A (zh) 在基因沉默中具有降低的脱靶效应的una寡聚物
JP2009533475A5 (enExample)
JP2009540011A5 (enExample)
JP2012072152A5 (enExample)
US20100305193A1 (en) Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
JP2010540564A5 (enExample)
JP2022185052A5 (enExample)
JP2006505251A5 (enExample)
RU2010117178A (ru) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
JP2013540770A5 (enExample)
JP2008533050A5 (enExample)
JP2022501044A5 (enExample)
US20150057336A1 (en) RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
JP2009533466A5 (enExample)
WO2015030616A4 (en) Use of nucleic acid molecules in therapy of diseases induced by expansion of trinucleotide cag repeats
KR20180039760A (ko) siRNA, 및 NRARP 유전자의 발현을 억제하기 위한 방법 및 조성물에서의 이의 용도
CN101124322B (zh) 用于治疗青光眼的血清淀粉状蛋白A的RNAi抑制
JP2024526234A5 (enExample)
WO2008092142A2 (en) Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization